Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer.

Competing Interests: The views expressed in this Comment are those of the authors and not necessarily those of the UK National Health Service, the National Institute for Health and Care Research (NIHR), or the UK Department of Health. ECS receives financial support from the NIHR Biomedical Research Centre in Oxford; receives grants and personal fees from Bristol Myers Squibb and AstraZeneca; receives personal fees from Amgen, Daiichi Sankyo, Mirati, Merck, Viracta, Astellas, Novartis, Pfizer, Zymeworks, and Beigene, outside the submitted work; receives non-financial support from Mirati; and is the European Organisation for Research and Treatment of Cancer Gastric Cancer Taskforce Chair and an Ireland Oesophagogastric Cancer Group Trustee. RS is on an advisory board for and receives honoraria for talks from Bristol Myers Squibb; is on an advisory board for and receives fees for travel from Eisai; is on an advisory board for and receives fees for talks and travel from Taiho and DiethelmKellerSiberHegner; is on an advisory board for and receives fees for talks and research funding from Merck Sharp & Dohme; is on an advisory board for Merck, Bayer, Novartis, GlaxoSmithKline, Astellas, Pierre-Fabre, and Tavotek; receives honoraria for talks from Eli Lilly; receives honoraria for talks and travel from Roche, AstraZeneca, and Ipsen; receives research funding and patents from Paxman Coolers; receives research funding from Natera; receives patents from Auristone, outside the submitted work; and has pending patents with Auristone, Paxman.